The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Lizneva D.V.

Kafedra akusherstva i ginekologii IPO Samarskogo gosudarstvennogo meditsinskogo universiteta;
ZAO "Meditsinskaia kompaniia IDK", Samara

Sinitsyna A.I.

Kafedra akusherstva i ginekologii IPO Samarskogo gosudarstvennogo meditsinskogo universiteta;
ZAO "Meditsinskaia kompaniia IDK", Samara

The impact of xenoestrogens, phytoestrogens and pharmaceutical estrogens on human health (a review)

Authors:

Lizneva D.V., Sinitsyna A.I.

More about the authors

Journal: Russian Journal of Human Reproduction. 2012;(4): 16‑22

Views: 21832

Downloaded: 418

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Lizneva DV, Lizneva DV, Sinitsyna AI, Sinitsyna AI. The impact of xenoestrogens, phytoestrogens and pharmaceutical estrogens on human health (a review). Russian Journal of Human Reproduction. 2012;(4):16‑22. (In Russ.)

 
МСФ на ЯМ
Close metadata
Recommended articles:
Ethi­nylestradiol and oral contraception: what we know after 60 years of use? (a review). Russian Journal of Human Reproduction. 2024;(4):90-100

Authors:

Lizneva D.V.

Kafedra akusherstva i ginekologii IPO Samarskogo gosudarstvennogo meditsinskogo universiteta;
ZAO "Meditsinskaia kompaniia IDK", Samara

Sinitsyna A.I.

Kafedra akusherstva i ginekologii IPO Samarskogo gosudarstvennogo meditsinskogo universiteta;
ZAO "Meditsinskaia kompaniia IDK", Samara

List of references:

  1. Speroff L., Fritz M.A. Clinical gynecologic endocrinology and infertility. Seventh edition. Chapter 2: hormone biosinthesis, methabolism, and mechanism of action. Lippincott Williams & Wilkins 2005; 25-97.
  2. Shanle E.K., Xu W. Endocrine disrupting chemicals targeting estrogen receptor signaling: identification and mechanisms of action. Chem Res Toxicol 2011; 24: 1: 6-19.
  3. Diamanti-Kandarakis E. et al. Endocrine-Disrupting Chemicals: An Endocrine Society Scientific Statement. Endocrine Rev 2009; 30: 4: 293-342.
  4. Euling S.Y., Selevan S.G., Pescovitz O.H., Skakkebaek N.E. Role of Environmental Factors in the Timing of Puberty. Pediatrics 2008; 121: 167.
  5. Aksglaede L., Sorensen K., Petersen J.H., Skakkebaek N.E., Juul A. Recent decline in age at breast development: the copenhagen puberty study. Pediatrics 2009; 123: e932-e939.
  6. Swan S.H., Elkin E.P., Fenster L. The question of declining sperm density revisited: an analysis of 101 studies published 1934-1996. Environ Health Perspect 2000; 108: 961-966.
  7. Joensen U.N., Jorgensen N., Rajpert-De Meyts E., Skakkebaek N.E. Testicular dysgenesis syndrome and Leydig cell function. Basic Clin Pharmacol Toxicol 2008; 102: 2: 155-161.
  8. Waye A., Trudeau V.L. Neuroendocrine disruption: more than hormones are upset. J Toxicol Environ Health B Crit Rev 2011; 14: 5-7: 270-291.
  9. Newbold R.R., Padilla-Banks E., Jefferson W.N. Adverse Effects of the Model Environmental Estrogen Diethylstilbestrol Are Transmitted to Subsequent Generations. Endocrinology 2006; 147: 6: Suppl: S11-S17.
  10. Giusti R.M., Iwamoto K., Hatch E.E. Diethylstilbestrol Revisited: A Review of the Long-Term Health Effects. Ann Intern Med 1995; 122: 778-788.
  11. Herbst A.L., Ulfelder H., Poskanzer D.C. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. New Engl J Med 1971; 284: 15: 878-881.
  12. Troisi R., Hatch E.E., Titus-Ernstoff L., Hyer M., Palmer J.R., Robboy S.J., Strohsnitter W.C., Kaufman R., Herbst A.L., Hoover R.N. Cancer risk in women prenatally exposed to diethylstilbestrol. Int J Cancer 2007; 121: 2: 356-360.
  13. Hoover R.N., Hyer M., Pfeiffer R.M., Adam E., Bond B., Cheville A.L., Colton T., Hartge P., Hatch E.E., Herbst A.L., Karlan B.Y., Kaufman R., Noller K.L., Palmer J.R., Robboy S.J., Saal R.C., Strohsnitter W., Titus-Ernstoff L., Troisi R. Adverse health outcomes in women exposed in utero to diethylstilbestrol. New Engl J Med 2011; 365: 14: 1304-1314.
  14. Office of Research on Women's Health, NIH, DHHS (2006-03). Status of Research on Uterine Fibroids (leiomyomata uteri) at the National Institutes of Health. United States National Institutes of Health. http://orwh.od.nih.gov/health/fibroidsrevisedmarch2006.pdf.
  15. Ehrhardt A.A., Meyer-Bahlburg H.F., Rosen L.R., Feldman J.F., Veridiano N.P., Zimmerman I., McEwen B.S. Sexual orientation after prenatal exposure to exogenous estrogen. Arch Sex Behav 1985; 14: 1: 57-77.
  16. Henderson B.E., Benton B., Cosgrove M., Baptista J., Aldrich J., Townsend D., Hart W., Mack T.M. Urogenital Tract Abnormalities in Sons of Women Treated With Diethylstilbestrol. Pediatrics 1976; 58: 4: 505-507.
  17. Gill W.B., Schumacher G.F., Bibbo M., Straus F.H., Schoenberg H.W. Association of diethylstilbestrol exposure in utero with cryptorchidism, testicular hypoplasia and semen abnormalities. J Urol 1979; 122: 36-39.
  18. Palmer J.R., Herbst A.L., Noller K.L., Boggs D.A., Troisi R., Titus-Ernstoff L., Hatch E.E., Wise L.A., Strohsnitter W.C., Hoover R.N. Urogenital abnormalities in men exposed to diethylstilbestrol in utero: a cohort study. Environmental Health 2009; 8: 37.
  19. Titus-Ernstoff L., Perez K., Hatch E.E., Troisi R., Palmer J.R., Hartge P., Hyer M., Kaufman R., Adam E., Strohsnitter W., Noller K., Pickett K.E., Hoover R. Psychosexual characteristics of men and women exposed prenatally to diethylstilbestrol. Epidemiology 2003; 14: 2: 155-160.
  20. Kuiper G.G., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., van der Saag P.T., van der Burg B., Gustafsson J.A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor ?. Endocrinology 1998; 139: 4252-4263.
  21. Geisz H.N., Dickhut R.M., Cochran M.A., Fraser W.R., Ducklow H.W. Melting Glaciers: A Probable Source of DDT to the Antarctic Marine Ecosystem. Environ Sci Technol 2005; ASAP: 3958.
  22. Hernik A., Góralczyk K., Struciński P., Czaja K., Kucharska A., Korcz W., Snopczyński T., Ludwicki J.K. Polybrominated diphenyl ethers, polychlorinated biphenyls and organochlorine pesticides in human milk as markers of environmental exposure to these compounds. Ann Agric Environ Med 2011; 18: 1: 113-118.
  23. Corsolini S., Borghesi N., Ademollo N., Focardi S. Chlorinated biphenyls and pesticides in migrating and resident seabirds from East and West Antarctica. Environ Int 2011; 37: 8: 1329-1335.
  24. Rogan W.J., Chen A. Health risks and benefits of bis(4-chlorophenyl)-1,1,1-trichloroethane (DDT). Lancet 2005; 366: 9487: 763-773.
  25. Venners S.A., Korrick S., Xu X. Preconception serum DDT and pregnancy loss: a prospective study using a biomarker of pregnancy. Am J Epidemiol 2005; 162: 8: 709-716.
  26. Rogan W.J., Ragan N.B. Evidence of effects of environmental chemicals on the endocrine system in children. Pediatrics 2003; 112: 1: Pt 2: 247-252.
  27. Sagiv S.K., Nugent J.K., Brazelton T.B. et al. Prenatal organochlorine exposure and measures of behavior in infancy using the Neonatal Behavioral Assessment Scale (NBAS). Environ Health Perspect 2008; 116: 5: 666-673.
  28. Ribas-Fitó N., Torrent M., Carrizo D. In utero exposure to background concentrations of DDT and cognitive functioning among preschoolers. Am J Epidemiol 2006; 164: 10: 955-962.
  29. Morales E., Sunyer J., Castro-Giner F., Estivill X., Julvez J., Ribas-Fitó N., Torrent M., Grimalt J.O., de Cid R. Environ Health Perspect. Influence of glutathione S-transferase polymorphisms on cognitive functioning effects induced by p,p'-DDT. Among Preschoolers 2008; 116: 11: 1581-1585.
  30. Nagayama J., Kohno H., Kunisue T. Concentrations of organochlorine pollutants in mothers who gave birth to neonates with congenital hypothyroidism. Chemosphere 2007; 68: 5: 972-976.
  31. Alvarez-Pedrerol M., Ribas-Fito N., Torrent M., Carrizo D., Grimalt J.O., Sunyer J. Effects of PCBs, p,p'-DDT, p,p'-DDE, HCB and {beta}-HCH on thyroid function in preschoolers. Occup Environ Med 2007; 65: 7: 452-457.
  32. Schell L.M., Gallo M.V., Denham M., Ravenscroft J., Decaprio A.P., Carpenter D.O. Relationship of Thyroid Hormone Levels to Levels of Polychlorinated Biphenyls, Lead, p, p'- DDE, and Other Toxicants in Akwesasne Mohawk Youth. Environ Health Perspect 2008; 116: 6: 806-813.
  33. National Institute of Environmental Health Sciences. Since you Asked - Bisphenol A. Questions and answers about the Draft National Toxicology Porgram Brief on Bisphenol A. ttp://www.niehs.nih.gov/news/media/questions/sya-bpa.cfm.
  34. Fleisch A.F., Sheffield P.E., Chinn C. et al. Bisphenol A and related compounds in dental materials. Pediatrics 2010; 126: 760.
  35. Calafat A.M., Ye X., Wong L.Y. et al. Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003-2004. Environ Health Perspect 2008; 116: 39.
  36. Toxicological and Health Aspects of Bisphenol A. Report of Joint FAO/WHO Expert Meeting, 2-5 November 2010.
  37. Lang I.A., Galloway T.S., Scarlett A. et al. Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA 2008; 300: 1303.
  38. Li D.K., Zhou Z., Miao M. et al. Urine bisphenol-A (BPA) level in relation to semen quality. Fertil Steril 2011; 95: 625.
  39. Webster P. Canada moves to protect babies from chemical. Lancet 2008; 371: 9630: 2074.
  40. Pediatric Environmental Health Specialty Units. Advisory about Phthalates and BPA. http://aoec.org/PEHSU/facts.html.
  41. Carwile J.L., Luu H.T., Bassett L.S. et al. Polycarbonate bottle use and urinary bisphenol A concentrations. Environ Health Perspect 2009; 117: 1368.
  42. Patisaul H.B., Jefferson W. The pros and cons of phytoestrogens. Front Neuroendocrinol 2010; 31: 4: 400-419.
  43. Kuiper G.G., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., van der Saag P.T., van der Burg B., Gustafsson J.A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor ?. Endocrinology 1998; 139:4252-4263.
  44. Kuhnle G.G.C., Dell'Aquila C., Aspinall S.M., Runswick S.A., Mulligan A.A., Bingham S.A. Phytoestrogen content of beverages, nuts, seeds, and oils. J Agric Food Chem 2008; 56: 7311-7315.
  45. Setchell K.D.L., Zimmer-Nechemias J., Cai J.E. Heubi, Isoflavone content of infant formulas and the metabolic fate of these phytoestrogens in early life. Am J Clin Nutr 1998; 68: 1453.
  46. Badger T.M., Ronis M.J., Hakkak R., Rowlands J.C., Korourian S. The health consequences of early soy consumption. J Nutr 2002; 132: 559S-565S.
  47. Winter J.S.D., Hughes I.A., Reyes F.I., Faiman C. Pituitary-gonadal relations in infancy: patterns of serum gonadal steroid concentrations in man from birth to two years of age. J Clin Endocrinol Metabol 1976; 42: 679-686.
  48. Mortensen A., Kulling S.E., Schwartz H., Rowland I., Ruefer C.E., Rimbach G., Cassidy A., Magee P., Millar J., Hall W.L., Kramer Birkved F., Sorensen I.K., Sontag G. Analytical and compositional aspects of isoflavones in food and their biological effects. Mol Nutr Food Res 2009; 53: Suppl 2: S266-S309.
  49. Kurzer M.S. Soy consumption for reduction of menopausal symptoms. Inflammopharmacology 2008; 16: 227-229.
  50. Jacobs A., Wegewitz U., Sommerfeld C., Grossklaus R., Lampen A. Efficacy of isoflavones in relieving vasomotor menopausal symptoms - a systematic review. Mol Nutr Food Res 2009; 53: 1084-1097.
  51. Kurzer M.S. Soy consumption for reduction of menopausal symptoms. Inflammopharmacology 2008; 16: 227-229.
  52. Shen W., Stearns V. Treatment strategies for hot flushes. Exp Opin Pharmacother 2009; 10: 1133-1144.
  53. Lethaby A.E., Brown J., Marjoribanks J., Kronenberg F., Roberts H., Eden J. Cochrane Database Syst Rev. Phytoestrogens for vasomotor menopausal symptoms 2007; 4: CD001395.
  54. The role of soy isoflavones in menopausal health: report of The North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010). Menopause 2011; 18: 7: 732-753.
  55. Liu J., Ho S.C., Su Y.X., Chen W.Q., Zhang C.X., Chen Y.M. Effect of long-term intervention of soyisoflavones on bone mineral density in women: a meta-analysis of randomized controlled trials. Bone 2009; 44: 948-953.
  56. Food and Drug Administration. Food labeling: health claims; soy protein and coronary heart disease. Food and Drug Administration, HHS. Final rule. Fed Regist 1999; 64: 57700-57733.
  57. Sacks F.M., Lichtenstein A., Van Horn L., Harris W., Kris-Etherton P., Winston M. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 2006; 113: 1034-1044.
  58. Wu A.H., Yu M.C., Tseng C.C., Pike M.C. Epidemiology of soy exposures and breast cancer risk. Br J Cancer 2008; 98: 9-14.
  59. Trock B.J., Hilakivi-Clarke L., Clarke R. Metaanalysis of soy intake and breast cancer risk. J Natl Cancer Inst 2006; 98: 459-471.
  60. Chandrareddy A., Muneyyirci-Delale O., McFarlane S.I., Murad O.M. Adverse effects of phytoestrogens on reproductive health: a report of three cases. Complement Ther Clin Pract 2008; 14: 132-135.
  61. Hooper L., Ryder J.J., Kurzer M.S., Lampe J.W., Messina M.J., Phipps W.R., Cassidy A. Effects of soy protein and isoflavones on circulating hormone concentrations in pre- and post-menopausal women: a systematic review and metaanalysis. Human Reprod Update 2009; 15: 423-440.
  62. Bernbaum J.C., Umbach D.M., Ragan N.B., Ballard J.L., Archer J.I., Schmidt-Davis H., Rogan W.J. Pilot studies of estrogen-related physical findings in infants. Environ Health Perspect 2008; 116: 416-420.
  63. Jensen J.T. Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest. Exp Opin Pharmacother 2010; 11: 7: 1147-1157.
  64. Rabe T. Contraception - Update and Trends. J Reproduktionsmed Endokrinol 2010; 7: 18-38.
  65. Sitruk-Ware R., Nath A. Metabolic effects of contraceptive steroids. Rev Endocr Metab Dis 2011; 12: 2: 63-75.
  66. Dinger J.C., Heinemann L.A.J., Kuhl-Habichl D. The safety of drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on Oral Contraceptives based on 142,475 women-years of observation. Contraception 2007; 75: 344-354.
  67. Junge W., Mellinger U., Parke S., Serrani. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study. Clin Drug Inv 2011; 31: 8: 573-584.
  68. Baillargeon J.P., McClish D.K., Essah P.A., Nestler J.E. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a metaanalysis. J Clin Endocrinol Metab 2006; 90: 3863-3870.
  69. Siritho S., Thrift A.G., McNeil J.J., You R.X., Davis S.M., Donnan G.A. Risk of ischemic stroke among users of the oral contraceptive pill. The Melbourne Risk Factor Study (MERFS) Group. Stroke 2003; 34: 1575-1580.
  70. Yang L., Kuper H., Sandin S., Margolis K.L., Chen Z., Adami H.O. et al. Reproductive history, oral contraceptive use, and the risk of ischemic and hemorrhagic stroke in a cohort study of middle-aged Swedish women. Stroke 2009; 40: 1050-1058.
  71. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996; 346: 505-510.
  72. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives:collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breastcancer from 54 epidemiological studies. Lancet 1996; 347: 1713-1727.
  73. Vessey M., Yeates D., Flynn S. Factors affecting mortality in a large cohort study with special reference to oralcontraceptive use. Contraception 2010; 82: 221-229.
  74. Hannaford P.C., Selvaraj S., Elliot A.M., Angus V., Iversen L., Lee A.J. Cancer risk among users of oral contraceptive: cohort data from the Royal College of General Practitioners' Oral Contraception Study. BMJ 2007; 335: 651.
  75. Vessey M., Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer 2006; 95: 385-389.
  76. Marchbanks P.A., McDonald J.A., Wilson H.G., Folger S.G., Mandel M.G., Daling J.R. et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002; 346: 2025-2032.
  77. Nichols H.B., Trentham-Dietz A., Egan K.M., Titus-Ernstoff L., Hampton J.M., Newcomb P.A. Oral contraceptive use and risk of breast carcinoma in situ. Cancer Epidemiol Biomarkers Prev 2007; 16: 2262-2268.
  78. Gill J.K., Press M.F., Ptel A.V., Brenstein L. Oral contraceptive use and risk of breast carcinoma in situ (United States). Cancer Causes Control 2006; 17: 1155-1162.
  79. Shapiro S., Rosenberg L., Hoffman M., Truter H., Cooper D., Rao S. et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol 2000; 151: 396-403.
  80. Vessey M., Yeates D., Flynn S. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. Contraception 2010; 82: 221-229.
  81. Fraser I.S. Forty years of combined oral contraception: the evolution of a revolution. Med J Aust 2000; 173: 10: 541-544.
  82. Schindler A.E. Non-contraceptive benefits of hormonal contraceptives. Minerva Ginecol 2010; 62: 4: 319-329.
  83. Cronin M., Schellschmidt I., Dinger J. Rate of pregnancy after using drospirenone and other progestin-containing oral contraceptives. Obstet Gynecol 2009; 114: 3: 616-622.
  84. Bagwell M.A., Thompson S.J., Addy C.L., Coker A.L., Baker E.R. Primary infertility and oral contraceptive steroid use. Fertil Steril 1995; 63: 6: 1161-1166.
  85. Rothman K.J. Fetal loss, twinning and birth weight after oral-contraceptive use. N Engl J Med 1977; 297: 9: 468-471.
  86. Ford J.H., MacCormac L. Pregnancy and lifestyle study: the long-term use of the contraceptive pill and the risk of age-related miscarriage. Hum Reprod 1995; 10: 6: 1397-1402.
  87. Jacobs H.S., Knuth U.A., Hull M.G., Franks S. Post-"pill" amenorrhoea-cause or coincidence? Br Med J 1977; 2: 6092: 940.
  88. Guoth J., Patai K., Siklósi G. Data throwing more light on the causes of postpill amenorrhoea. Ther Hung 1987; 35: 2: 80-84.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.